Pyxis Oncology Inc
Veridion Score
BETALOW CONF · 4/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is PYXS moving today?
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
PYXS overview
Related filings and maps
Congress activity in PYXS
No receipt-qualified Congressional disclosure is present for PYXS in the cached public ledger.
PYXS contract awards, year to date.
Public federal awards linked to this ticker.
PYXS lobbying filings, year to date.
Registered lobbying filings matched to Pyxis Oncology Inc.